OTCMKTS:PHGUF Pharming Group (PHGUF) Stock Price, News & Analysis $1.15 0.00 (0.00%) As of 07/3/2025 Add Compare Share Share Stock Analysis Stock AnalysisChartHeadlinesShort InterestBuy This Stock About Pharming Group Stock (OTCMKTS:PHGUF) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Pharming Group alerts:Sign Up Key Stats Today's Range$1.15▼$1.1550-Day Range$0.89▼$1.1952-Week Range$0.75▼$1.19VolumeN/AAverage Volume74 shsMarket Capitalization$771.73 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Pharming Group NV is a biotechnology company headquartered in Leiden, the Netherlands, specializing in the development and commercialization of protein replacement therapies for rare diseases. Founded in 1988, the company leverages its proprietary technology platform to produce recombinant human proteins in transgenic animals, aiming to address conditions with high unmet medical need. Pharming’s flagship product is RUCONEST, a recombinant C1 esterase inhibitor indicated for the treatment and prevention of hereditary angioedema (HAE) attacks. RUCONEST is marketed in North America, Europe and several other territories through a combination of direct sales and strategic partnerships. In addition to its core HAE franchise, Pharming is advancing a pipeline of next-generation enzyme replacement therapies and prophylactic biologics targeting rare genetic disorders and acute respiratory conditions. The company has preclinical and clinical stage programs focused on novel protein candidates designed to restore deficient or dysfunctional enzymes in patient populations. Pharming Group serves patients and healthcare providers across the United States, the European Union and other global markets. The company maintains manufacturing operations in the Netherlands, ensuring compliance with stringent quality standards for biologic production. Pharming’s management team comprises experienced professionals in biotechnology research, regulatory affairs and commercial strategy, reinforcing its commitment to expand access to life-saving therapies for rare disease communities around the world.AI Generated. May Contain Errors. Read More Receive PHGUF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pharming Group and its competitors with MarketBeat's FREE daily newsletter. Email Address PHGUF Stock News HeadlinesPharming Group (PHGN.DU)June 26, 2025 | sg.finance.yahoo.comPharming Group N.V.: Pharming Group reports on results of the 2025 Annual General Meeting of ShareholdersJune 11, 2025 | finanznachrichten.deA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again. July 5 at 2:00 AM | Porter & Company (Ad)Pharming Group (PHGUF) Q1 2025 Earnings Call Highlights: Revenue Surge and Strategic Growth ...May 9, 2025 | uk.finance.yahoo.comPharming Group announces upcoming presentations at the 2025 Annual Meeting of the Clinical Immunology Society (CIS)April 25, 2025 | finance.yahoo.comPharming announces positive recommendation from NICE for JoenjaApril 24, 2025 | finance.yahoo.comPharming Group to report first quarter 2025 financial results on May 8April 24, 2025 | finance.yahoo.comPharming Group N.V.: Pharming receives positive recommendation from NICE for Joenja?(leniolisib) as a treatment for APDSApril 23, 2025 | finanznachrichten.deSee More Headlines PHGUF Stock Analysis - Frequently Asked Questions How have PHGUF shares performed this year? Pharming Group's stock was trading at $0.9815 at the beginning of the year. Since then, PHGUF stock has increased by 17.2% and is now trading at $1.15. How were Pharming Group's earnings last quarter? Pharming Group NV (OTCMKTS:PHGUF) posted its quarterly earnings data on Thursday, March, 5th. The biotechnology company reported $0.05 EPS for the quarter, beating the consensus estimate of $0.04 by $0.01. Pharming Group had a negative net margin of 4.14% and a negative trailing twelve-month return on equity of 6.01%. How do I buy shares of Pharming Group? Shares of PHGUF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings3/05/2015Today7/05/2025Next Earnings (Estimated)7/31/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry MED - BIOMED/GENE Sub-IndustryN/A Current SymbolOTCMKTS:PHGUF Previous SymbolOTC:PHGUF CIKN/A Webwww.pharming.com Phone(171) 524-7400Fax31-0-71-524-7445Employees382Year FoundedN/AProfitability EPS (Trailing Twelve Months)($0.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$11.84 million Net Margins-4.14% Pretax Margin-1.14% Return on Equity-6.01% Return on Assets-3.23% Debt Debt-to-Equity Ratio0.51 Current Ratio2.76 Quick Ratio2.00 Sales & Book Value Annual Sales$297.20 million Price / Sales2.60 Cash Flow$0.01 per share Price / Cash Flow153.03 Book Value$0.33 per share Price / Book3.48Miscellaneous Outstanding Shares671,070,000Free FloatN/AMarket Cap$771.73 million OptionableNot Optionable Beta0.60 Social Links 20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free Report This page (OTCMKTS:PHGUF) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pharming Group NV Please log in to your account or sign up in order to add this asset to your watchlist. Share Pharming Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.